IL154692A0 - Method of treating erectile dysfunction and increasing libido in men - Google Patents
Method of treating erectile dysfunction and increasing libido in menInfo
- Publication number
- IL154692A0 IL154692A0 IL15469201A IL15469201A IL154692A0 IL 154692 A0 IL154692 A0 IL 154692A0 IL 15469201 A IL15469201 A IL 15469201A IL 15469201 A IL15469201 A IL 15469201A IL 154692 A0 IL154692 A0 IL 154692A0
- Authority
- IL
- Israel
- Prior art keywords
- testosterone
- kits
- compositions
- combinations
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/651,777 US6503894B1 (en) | 2000-08-30 | 2000-08-30 | Pharmaceutical composition and method for treating hypogonadism |
US70375300A | 2000-11-01 | 2000-11-01 | |
PCT/US2001/027205 WO2002017927A1 (fr) | 2000-08-30 | 2001-08-29 | Methode pour traiter la dyserection et augmenter la libido chez l'homme |
Publications (1)
Publication Number | Publication Date |
---|---|
IL154692A0 true IL154692A0 (en) | 2003-09-17 |
Family
ID=27096141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15469201A IL154692A0 (en) | 2000-08-30 | 2001-08-29 | Method of treating erectile dysfunction and increasing libido in men |
Country Status (22)
Country | Link |
---|---|
US (1) | US20050054623A1 (fr) |
EP (2) | EP2283865A1 (fr) |
JP (1) | JP2004524267A (fr) |
KR (1) | KR100861603B1 (fr) |
CN (1) | CN1473047A (fr) |
AT (1) | ATE460939T1 (fr) |
AU (2) | AU8699501A (fr) |
BR (1) | BR0113651A (fr) |
CA (2) | CA2420895C (fr) |
CY (1) | CY1110085T1 (fr) |
DE (1) | DE60141587D1 (fr) |
DK (1) | DK1315502T3 (fr) |
ES (1) | ES2341090T3 (fr) |
IL (1) | IL154692A0 (fr) |
MX (1) | MXPA03001858A (fr) |
NO (1) | NO332649B1 (fr) |
NZ (1) | NZ524601A (fr) |
PL (1) | PL205279B1 (fr) |
PT (1) | PT1315502E (fr) |
SI (1) | SI1315502T1 (fr) |
TR (1) | TR200300776T2 (fr) |
WO (1) | WO2002017927A1 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
JP5039252B2 (ja) * | 2000-08-31 | 2012-10-03 | ユニメッド ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 性機能低下を治療するための医薬組成物及び方法 |
MY139721A (en) | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
BRPI0312007B1 (pt) | 2002-06-25 | 2015-04-14 | Acrux Dds Pty Ltd | Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição |
AUPS317302A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Metastable pharmaceutical compositions |
IL152575A (en) | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
IL152573A (en) | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
JP2007537247A (ja) | 2004-05-11 | 2007-12-20 | エモーショナル ブレイン ビー.ブイ. | 女性性的機能不全の治療における薬学的製剤およびその使用方法 |
EP1634583A1 (fr) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Gels de testostérone comprenant du propylèneglycol comme promoteur d'absorption |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
BRPI0611134A2 (pt) | 2005-06-03 | 2010-08-17 | Acrux Dds Pty Ltd | método e composição para liberação transdérmica de fármaco |
CA2610708C (fr) * | 2005-06-03 | 2013-10-08 | Acrux Dds Pty Ltd | Methode et composition pour l'administration transdermique d'un medicament |
US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
TR201815853T4 (tr) | 2005-10-12 | 2018-11-21 | Besins Healthcare Sarl | Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli. |
EP1790343A1 (fr) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme |
US8613360B2 (en) | 2006-09-29 | 2013-12-24 | M-I L.L.C. | Shaker and degasser combination |
EP1925307A1 (fr) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles |
GB2461725B (en) | 2008-07-10 | 2012-06-13 | United Wire Ltd | Improved sifting screen |
US20100061976A1 (en) * | 2008-07-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
US20100022991A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and device for maintaining physiological levels of steroid hormone in a subject |
US20110190201A1 (en) * | 2008-07-24 | 2011-08-04 | Searete Llc | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
US20100022497A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject |
US20100022494A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
MY169998A (en) | 2010-05-12 | 2019-06-19 | Pomerleau Mech Inc | Systems and methods for drying drill cuttings |
RU2474424C2 (ru) * | 2010-09-24 | 2013-02-10 | Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин |
AU2011329782A1 (en) | 2010-11-18 | 2013-06-20 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
US9795639B1 (en) * | 2013-03-16 | 2017-10-24 | BioDlogics, LLC | Methods for the treatment of erectile dysfunction by human birth tissue material compostion |
US8785426B1 (en) | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
JP2021512868A (ja) * | 2018-02-02 | 2021-05-20 | エイセルス バイオファーマ インコーポレイテッド | テストステロン療法の方法 |
EP4054549A4 (fr) | 2019-11-06 | 2023-12-06 | Smartech Topical, Inc. | Formulations topiques d'inhibiteurs de la cyclo-oxygénase et leur utilisation |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
US4855305A (en) * | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
TW224048B (fr) * | 1992-03-30 | 1994-05-21 | Hoechst Roussel Pharma | |
JPH08501529A (ja) * | 1992-06-11 | 1996-02-20 | セラテック・インコーポレイテッド | 皮膚透過薬剤投与緩和のグリセリン使用 |
US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
JP4036496B2 (ja) * | 1995-10-24 | 2008-01-23 | リンテック株式会社 | ゲル製剤の製造方法 |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5730987A (en) * | 1996-06-10 | 1998-03-24 | Omar; Lotfy Ismail | Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
GB9700878D0 (en) * | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
JP2001512440A (ja) * | 1997-02-07 | 2001-08-21 | セラテック・インコーポレーテッド | テストステロンの欠乏症状を持つ女性のテストステロン補充のための組生物および方法 |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
IL136042A (en) * | 1997-11-10 | 2005-12-18 | Cellegy Pharma Inc | Alcohol-containing composition for topical application |
ATE303774T1 (de) * | 1998-06-25 | 2005-09-15 | Lavipharm Lab Inc | Vorrichtung und verfahren zur behandlung von erektionsstörungen |
JP2000225116A (ja) * | 1998-12-04 | 2000-08-15 | Eisai Co Ltd | 陰茎径の測定法 |
JP2000212080A (ja) * | 1999-01-26 | 2000-08-02 | Hiroshi Azuma | 勃起機能不全改善剤 |
DE19903087A1 (de) * | 1999-01-27 | 2000-08-10 | Forssmann Wolf Georg | Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern |
PT1150661E (pt) * | 1999-02-05 | 2004-02-27 | Cipla Ltd | Produto para pulverizacao para aplicacao topica |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
-
2001
- 2001-08-29 SI SI200130964T patent/SI1315502T1/sl unknown
- 2001-08-29 PT PT01966486T patent/PT1315502E/pt unknown
- 2001-08-29 BR BR0113651-8A patent/BR0113651A/pt not_active Application Discontinuation
- 2001-08-29 JP JP2002522900A patent/JP2004524267A/ja active Pending
- 2001-08-29 KR KR1020037003148A patent/KR100861603B1/ko active IP Right Grant
- 2001-08-29 CN CNA018172660A patent/CN1473047A/zh active Pending
- 2001-08-29 NZ NZ524601A patent/NZ524601A/en not_active IP Right Cessation
- 2001-08-29 ES ES01966486T patent/ES2341090T3/es not_active Expired - Lifetime
- 2001-08-29 IL IL15469201A patent/IL154692A0/xx active IP Right Grant
- 2001-08-29 CA CA002420895A patent/CA2420895C/fr not_active Expired - Lifetime
- 2001-08-29 DK DK01966486.1T patent/DK1315502T3/da active
- 2001-08-29 AU AU8699501A patent/AU8699501A/xx active Pending
- 2001-08-29 AT AT01966486T patent/ATE460939T1/de active
- 2001-08-29 TR TR2003/00776T patent/TR200300776T2/xx unknown
- 2001-08-29 CA CA2746787A patent/CA2746787A1/fr not_active Abandoned
- 2001-08-29 PL PL366037A patent/PL205279B1/pl unknown
- 2001-08-29 WO PCT/US2001/027205 patent/WO2002017927A1/fr active Application Filing
- 2001-08-29 DE DE60141587T patent/DE60141587D1/de not_active Expired - Lifetime
- 2001-08-29 EP EP10184108A patent/EP2283865A1/fr not_active Withdrawn
- 2001-08-29 EP EP01966486A patent/EP1315502B1/fr not_active Expired - Lifetime
- 2001-08-29 MX MXPA03001858A patent/MXPA03001858A/es active IP Right Grant
- 2001-08-29 AU AU2001286995A patent/AU2001286995B2/en not_active Expired
-
2003
- 2003-02-28 NO NO20030955A patent/NO332649B1/no not_active IP Right Cessation
-
2004
- 2004-02-25 US US10/787,071 patent/US20050054623A1/en not_active Abandoned
-
2010
- 2010-06-15 CY CY20101100550T patent/CY1110085T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1473047A (zh) | 2004-02-04 |
NO20030955D0 (no) | 2003-02-28 |
PL366037A1 (en) | 2005-01-24 |
MXPA03001858A (es) | 2004-05-21 |
BR0113651A (pt) | 2004-11-09 |
JP2004524267A (ja) | 2004-08-12 |
ATE460939T1 (de) | 2010-04-15 |
US20050054623A1 (en) | 2005-03-10 |
WO2002017927A1 (fr) | 2002-03-07 |
KR20030043949A (ko) | 2003-06-02 |
KR100861603B1 (ko) | 2008-10-07 |
PT1315502E (pt) | 2010-05-06 |
NO332649B1 (no) | 2012-11-26 |
AU2001286995B2 (en) | 2006-11-30 |
CA2420895A1 (fr) | 2002-03-07 |
EP2283865A1 (fr) | 2011-02-16 |
EP1315502A1 (fr) | 2003-06-04 |
CY1110085T1 (el) | 2015-01-14 |
NO20030955L (no) | 2003-04-28 |
PL205279B1 (pl) | 2010-03-31 |
TR200300776T2 (tr) | 2005-10-21 |
CA2420895C (fr) | 2007-03-13 |
SI1315502T1 (sl) | 2010-07-30 |
CA2746787A1 (fr) | 2002-03-07 |
NZ524601A (en) | 2006-04-28 |
AU8699501A (en) | 2002-03-13 |
DK1315502T3 (da) | 2010-07-19 |
DE60141587D1 (de) | 2010-04-29 |
ES2341090T3 (es) | 2010-06-15 |
EP1315502B1 (fr) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU8699501A (en) | Method for treating erectile dysfunction and increasing libido in men | |
MXPA03001859A (es) | Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados. | |
Haynes et al. | The pharmacology of letrozole | |
WO2003002123A3 (fr) | Combinaisons therapeutiques pour le traitement des carences hormonales | |
IL149448A0 (en) | New topical estrogen-progestogen compositions with a systemic effect | |
WO2006113242A3 (fr) | Procede d'augmentation de la testosterone et concentrations steroidiennes correspondantes chez la femme | |
PL357944A1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
MD1920F2 (ro) | Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer | |
YU54602A (sh) | Drospirenon za terapiju zamene hormona | |
HK1071521A1 (en) | Use of a composition comprising cis-clomiphene andtrans-clomiphene in the preparation of a medicament for increasing serum levels of testosterone | |
MXPA02007117A (es) | Composiciones para suministrar un antagonista de cortisol.. | |
WO2002058706A3 (fr) | Methode de traitement de deficiences hormonales chez des femmes sous oestrogenotherapie substitutive | |
BR9807828A (pt) | Composições e método para a suplementação de testosterona em mulheres com sintomas de deficiência de testosterona | |
BR0114665A (pt) | Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio | |
HK1127556A1 (en) | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases | |
MXPA02004084A (es) | Nueva composicion hormonal y su utilizacion. | |
BR0308584A (pt) | Composição farmacêutica androgênica e método para tratamento de depressão | |
BR0214643A (pt) | Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite | |
HUP9901505A2 (hu) | Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására | |
WO2002039995A3 (fr) | Traitement combine de maladies dependantes des oestrogenes | |
AR032390A1 (es) | Uso de gestagenos para inhibir la maduracion acelerada del endometrio durante el tratamiento de la infertilidad | |
BR0117195A (pt) | Métodos para o tratamento ou profilaxia de efeitos patogênicos mediados por aldosterona em um sujeito que usa um epóxi esteroidal antagonista da aldosterona | |
EA200300322A1 (ru) | 4-галогенированные 17-метиленстероиды, способ их получения и содержащие эти соединения фармацевтические композиции | |
AR038904A1 (es) | Metodo para incrementar en la mujer las concentraciones de testosterona y esteroides relacionados | |
VARAVUDHI | Induction by androgens of nidation in pregnant rats deprived of gonadotrophin secretion by trifluoperazine injections and by lactation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed |